CD8A and neoplasm: Indeed, among stage pT3, N0 tumours—where MMR status often guides decisions on adjuvant chemotherapy1—we found no evidence that CD8+ cell density was independently prognostic, suggesting that further work is required to identify immune biomarkers of clinical value in this subgroup.